Author Identity
Mr. and Mrs. Zhang walked into the office with a report showing they were carriers of beta-thalassemia. The couple plans to undergo third-generation IVF in Kyrgyzstan, and their biggest concern is: "How much will PGT genetic screening actually cost? Will it exceed our budget?" This is a question almost every family with genetic risks asks. Today, we answer it with a real cost breakdown.
Kyrgyzstan PGT Genetic Screening Cost: Direct Answer
In Kyrgyzstan, the cost of PGT genetic screening is mainly determined by the type of screening and the number of embryos. Based on quotes from multiple reproductive centers in 2025, the cost ranges are as follows:
| Screening Type | Cost Range (RMB) | Description |
|---|---|---|
| PGT-A (Aneuploidy Screening) | 15,000 – 30,000 RMB / cycle | Detects chromosomal number abnormalities. Suitable for advanced maternal age, recurrent miscarriage, and repeated implantation failure. |
| PGT-M (Monogenic Disease Screening) | 30,000 – 60,000 RMB / cycle | For known monogenic genetic diseases. Requires prior family verification. |
| PGT-SR (Chromosomal Structural Rearrangement) | 25,000 – 50,000 RMB / cycle | Applicable for structural abnormalities like balanced translocations and Robertsonian translocations. |
Note: The above costs only include embryo biopsy, genetic testing, and basic genetic counseling. They do not include IVF ovulation induction, egg retrieval, embryo culture, transfer, or medication costs. The total cost for a complete third-generation IVF cycle (including PGT-A) in Kyrgyzstan is typically 80,000 – 130,000 RMB.
The 'Variables' Behind the Cost: What Factors Affect the Final Bill
For the same PGT screening, the final cost for different families can vary by a factor of two. The core variables include:
- Number of Embryos: Most clinics charge based on the "number of embryos." The cost differs for testing 1 embryo versus 6 embryos. Packages usually include 3-4 embryos, with an additional charge of 2,000-4,000 RMB per extra embryo.
- Testing Technology Platform: NGS (Next-Generation Sequencing) is the mainstream method and costs more than traditional FISH or aCGH. NGS offers higher resolution and can detect mosaicism, but it is also more expensive.
- Need for Family Verification: Before PGT-M testing, genetic verification of both partners and the proband (if available) is mandatory. This verification costs approximately 3,000-8,000 RMB and is charged separately.
- Hospital Level and Laboratory Accreditation: Centers with their own genetics laboratory usually charge more than those outsourcing testing, but they offer better quality control.
- Whether Embryo Freezing is Included: After screening results are ready, healthy embryos need to be frozen for storage. The freezing fee is typically 2,000-4,000 RMB per year and is not included in the screening fee.
Cost Simulation for Different Numbers of Embryos (PGT-A, NGS Platform)
| Number of Embryos Tested | Estimated Cost (RMB) | Remarks |
|---|---|---|
| 1 – 3 embryos | 18,000 – 25,000 RMB | Basic package, suitable for younger women with good ovarian function. |
| 4 – 6 embryos | 25,000 – 38,000 RMB | Most common range, chosen by most families. |
| 7 – 10 embryos | 38,000 – 55,000 RMB | Need to confirm if the lab's testing throughput supports this. |
Kyrgyzstan vs. Other Countries: Cost and Value Comparison
Why choose Kyrgyzstan for PGT? Cost advantage is a major factor, but not the only one. The table below compares popular destinations:
| Country/Region | PGT-A Cost (RMB) | Total Third-Generation IVF Cost (Approx.) | Laboratory Accreditation |
|---|---|---|---|
| Kyrgyzstan | 15,000 – 30,000 | 80,000 – 130,000 | CLIA / CAP Reference Standards |
| Thailand | 25,000 – 45,000 | 100,000 – 160,000 | International JCI Accreditation |
| United States | 30,000 – 50,000 (USD equivalent) | 200,000 – 350,000 | CAP / CLIA Accreditation |
| Georgia | 18,000 – 32,000 | 70,000 – 120,000 | European Standards Reference |
Doctor's Perspective: The cost of PGT in Kyrgyzstan is at the lower end internationally, but laboratories mostly use imported NGS reagents and platforms (such as Illumina), ensuring testing quality. It is suitable for families with limited budgets but who need reliable genetic screening.
4 Most Easily Overlooked Details
Based on real consultation cases, the following details are often overlooked but directly impact cost and screening success:
- Timing of Embryo Biopsy: PGT screening requires biopsy at the blastocyst stage (day 5-6). If embryos develop slowly and cannot form blastocysts, screening is not possible. Is this fee refundable? — Most centers do not refund the testing fee, only part of the culture fee.
- Genetic Counseling Fee: Some clinics' PGT fees do not include post-procedure genetic counseling, which costs 500-1,500 RMB per session. Interpreting the screening report is very important and should not be skipped.
- Mosaic Embryo Handling: NGS testing may detect mosaic embryos (a mix of normal and abnormal cells). Does this require a second biopsy or re-testing? This incurs additional costs of about 3,000-6,000 RMB.
- Cycle Continuity: If no transferable embryos are available after screening, a new ovulation induction cycle is needed, incurring the full PGT cost again. About 15%-25% of PGT-A cycles require a second stimulation due to a lack of euploid embryos.
Practitioner's Observation: Many families only focus on the "unit price" but overlook the hidden cost of "cycle success rate." When choosing a lab, it is advisable to ask: "If there are no transferable embryos this cycle, is there a discount on PGT fees for the next cycle?" Some centers offer a 20-30% discount for a second cycle.
Kyrgyzstan PGT Genetic Screening: Process from Start to Transfer
Understanding the process helps assess whether the cost is reasonable and the time required for each step:
- Initial Assessment and Family Verification (2-4 weeks): Blood draw from both partners for genetic verification. For PGT-M, the pathogenic variant must be confirmed first. Cost: approx. 3,000-8,000 RMB.
- IVF Cycle (2-3 weeks): Ovulation induction, egg retrieval, fertilization, and blastocyst culture. PGT begins once the blastocyst stage is reached.
- Embryo Biopsy (1 day): The lab extracts 3-5 cells from the trophectoderm of the blastocyst for testing. Biopsy cost is included in the PGT package.
- Genetic Testing (7-14 days): Sequencing and analysis using the NGS platform. Embryos are frozen while waiting for the report.
- Genetic Counseling and Report Interpretation (1-2 days): A doctor or genetic counselor explains the results and identifies transferable euploid embryos.
- Transfer Preparation (4-6 weeks): Preparation of the endometrium for a frozen embryo transfer.
The entire process from start to transfer takes approximately 3-4 months, with PGT testing taking 7-14 days. For PGT-M, the family verification phase requires an additional 2-4 weeks.
Doctor's Decision Logic: Who Really Needs PGT?
At reproductive centers in Kyrgyzstan, the indications for recommending PGT screening are very clear. Not everyone needs it. Doctors strongly recommend it in the following situations:
- Female age ≥ 38 years: The rate of embryonic aneuploidy increases significantly. PGT-A can improve the live birth rate per single transfer.
- Recurrent miscarriage (≥2): About 50%-60% of early miscarriages are caused by chromosomal abnormalities.
- Repeated implantation failure (≥3): After excluding embryonic factors, PGT can screen for euploid embryos.
- Known monogenic genetic diseases: Such as thalassemia, spinal muscular atrophy, hereditary deafness, etc. PGT-M is mandatory.
- Chromosomal structural abnormalities: Carriers of balanced translocations or Robertsonian translocations have a very high risk of miscarriage.
When is it not suitable?
- Very low ovarian reserve (AMH < 0.5 ng/mL): Few eggs are retrieved, making it difficult to form enough blastocysts for screening. PGT has limited value.
- Low number of embryos (< 3 blastocysts): After screening, there may be no euploid embryos available for transfer, incurring the cost risk.
- Simply for "gender selection": In Kyrgyzstan, non-medical gender selection is not encouraged, and the high cost of PGT makes it poor value for money.
Doctor's Advice: Before making a PGT decision, complete a basic fertility assessment (AMH, antral follicle count, semen analysis). If egg retrieval potential is limited, prioritize an embryo accumulation strategy rather than immediately starting a PGT cycle.
Frequently Asked Questions & Real Answers
Q1: What is the success rate of transferring one euploid embryo after PGT screening?
According to data from multiple centers in Kyrgyzstan, transferring one euploid blastocyst screened by PGT-A results in a clinical pregnancy rate of approximately 55%-70%, higher than unscreened embryos (35%-45%). However, success is still influenced by factors like female age, uterine environment, and metabolic status.
Q2: How accurate is PGT screening in Kyrgyzstan?
PGT-A using the NGS platform has an accuracy of about 95%-98%, with a 2%-5% risk of false positives or false negatives. This is mainly due to embryonic mosaicism or limitations of amplification technology. The accuracy of PGT-M depends on the specific variant and is generally > 99%.
Q3: Does PGT screening harm the embryo?
Biopsy is performed by experienced embryologists. After removing 3-5 cells from the blastocyst, the embryo survival rate is > 95%. The current mainstream view is that biopsy does not increase the risk of birth defects. However, the embryo must be frozen after biopsy, and the freeze-thaw process has a certain loss rate (about 5%-10%).
Q4: Can I do only PGT in Kyrgyzstan without IVF?
No. PGT must be performed on embryos obtained through an IVF cycle and cannot be done independently.
Q5: If there are no transferable embryos after screening, is the fee refundable?
PGT testing fees are generally non-refundable because the testing service has been completed. However, some clinics offer a "second cycle discount" or "partial testing fee credit." It is advisable to confirm these terms before signing the informed consent form.
Risk Reminder: PGT genetic screening is an advanced embryo selection technology, but it cannot detect all genetic diseases (such as polygenic disorders or de novo mutations) and cannot completely prevent miscarriage or birth defects. Embryos with normal screening results still carry a residual risk of about 1%-3%. Additionally, in about 15%-25% of PGT cycles, no euploid embryos are available for transfer, requiring thorough financial and psychological preparation. It is recommended to make a rational decision based on your own situation under the guidance of a genetic counselor.